For stage II CRC, 77% (23/30) were PPP1R3C methylation(+), whereas only 40% (12/30) were CEA(+) (P = 0.004) and 13% (4/30) were CA19-9(+) (P = 7 × 10−7). The gene discussed is PPP1R3C; the disease is colorectal carcinoma.